GeneDx (NASDAQ:WGS) PT Raised to $15.00 at BTIG Research

GeneDx (NASDAQ:WGS) had its price target raised by research analysts at BTIG Research from $11.00 to $15.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price points to a potential upside of 25.00% from the stock’s current price.

Separately, The Goldman Sachs Group raised their target price on shares of GeneDx to $11.00 and gave the stock a “neutral” rating in a research note on Monday, April 15th.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $12.00 on Monday. The firm’s 50-day moving average price is $8.87 and its 200-day moving average price is $4.87. The company has a quick ratio of 2.95, a current ratio of 3.10 and a debt-to-equity ratio of 0.23. The company has a market cap of $312.60 million, a PE ratio of -1.61 and a beta of 2.75. GeneDx has a 52-week low of $1.16 and a 52-week high of $12.57.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. The firm had revenue of $57.42 million for the quarter, compared to the consensus estimate of $57.00 million. GeneDx had a negative net margin of 86.77% and a negative return on equity of 49.64%. As a group, analysts anticipate that GeneDx will post -2.02 EPS for the current year.

Insider Transactions at GeneDx

In other news, CEO Katherine Stueland sold 8,559 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $90,639.81. Following the transaction, the chief executive officer now owns 66,698 shares of the company’s stock, valued at $706,331.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Casdin Capital, Llc acquired 40,000 shares of the business’s stock in a transaction on Monday, March 4th. The shares were acquired at an average price of $8.74 per share, for a total transaction of $349,600.00. Following the completion of the transaction, the director now directly owns 2,702,609 shares of the company’s stock, valued at approximately $23,620,802.66. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 8,559 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $10.59, for a total transaction of $90,639.81. Following the transaction, the chief executive officer now owns 66,698 shares in the company, valued at approximately $706,331.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,820 shares of company stock valued at $146,354. 28.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of WGS. Oracle Investment Management Inc. lifted its stake in GeneDx by 14.9% in the third quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company’s stock worth $3,620,000 after acquiring an additional 128,731 shares during the period. HighTower Advisors LLC lifted its position in shares of GeneDx by 14.1% during the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company’s stock valued at $865,000 after buying an additional 29,361 shares during the last quarter. Trellus Management Company LLC lifted its position in shares of GeneDx by 55.0% during the third quarter. Trellus Management Company LLC now owns 155,012 shares of the company’s stock valued at $564,000 after buying an additional 54,976 shares during the last quarter. Decheng Capital LLC purchased a new stake in shares of GeneDx during the fourth quarter valued at about $285,000. Finally, Pathstone Family Office LLC lifted its position in shares of GeneDx by 262.2% during the third quarter. Pathstone Family Office LLC now owns 54,327 shares of the company’s stock valued at $198,000 after buying an additional 39,327 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.